From Oral to Sublingual: A Redefined Avanafil Tablet with a Breakthrough in Bioavailability and First-Pass Metabolism Avoidance
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s504291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Turky Omar Asar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Science and Arts at Alkamil, University of Jeddah, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Pyrimidines, Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, College of Science and Arts at Alkamil, University of Jeddah, Jeddah, Saudi Arabia.
- Department of Pharmaceutics, Faculty of Pharm Saudi Arabia Acy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Egyptian Russian University, Cairo, 11829, Egypt.
- College of Pharmacy, Kut University, Wasit, 52001, Iraq.
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, 11651, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
ORCID-Profile: Turky Omar Asar, Hossam S El-Sawy, Abdelsattar M Omar, Khalid M El-Say
Zitieren
APA
Asar, T. O., Al-Hejaili, O. D., El-Sawy, H. S., Abd-Allah, F. I., Omar, A. M., Ahmed, T. A., & El-Say, K. M. (2025). From Oral to Sublingual: A Redefined Avanafil Tablet with a Breakthrough in Bioavailability and First-Pass Metabolism Avoidance. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s504291
Vancouver
Asar TO, Al-Hejaili OD, El-Sawy HS, Abd-Allah FI, Omar AM, Ahmed TA, et al. From Oral to Sublingual: A Redefined Avanafil Tablet with a Breakthrough in Bioavailability and First-Pass Metabolism Avoidance. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s504291
BibTeX
@article{Asar2025,
author = {Asar, Turky Omar and Al-Hejaili, Omar D and El-Sawy, Hossam S and Abd-Allah, Fathy I and Omar, Abdelsattar M and Ahmed, Tarek A and El-Say, Khalid M},
title = {From Oral to Sublingual: A Redefined Avanafil Tablet with a Breakthrough in Bioavailability and First-Pass Metabolism Avoidance},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s504291}
}
EUVIMED